



#3

PATENT
Customer No. 22,852
Attorney Docket No. 2356.0011-10

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Marc ALIZON et al.) Group Art Unit: 1648
)
Application No.: 10/076,370) Examiner: Not yet assigned
)
Filed: February 19, 2002) Confirmation No. 2811
)
For: A VARIANT OF LAV VIRUSES)

Commissioner for Patents
Washington, DC 20231

RECEIVED
MAY 20 2002
TECH CENTER 1600/2900

Sir:

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AMINO ACID SEQUENCE DISCLOSURES**

This paper is filed in response to the Notice dated April 24, 2002.

Applicants submit that this application does not need to comply with the Sequence Rules because its effective U.S. filing date is April 13, 1987, the filing date of Application No. 07/038,330 (now U.S. Patent No. 5,030,714). The Sequence Rules 37 C.F.R. §§ 1.821-1.825 are not effective for applications whose effective U.S. filing date is prior to October 1, 1990. Accordingly, no sequence listing is required

If there is any fee due in connection with the filing of this response, please charge the fee to our deposit account 06-0916.

FINNEGAN
ENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: May 16, 2002

By: Rebecca McNeill
Rebecca M. McNeill
Reg. No. 43,796



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/076,370	02/19/2002	Marc Alizon	2356-0011-10000

CONFIRMATION NO. 2811

22852
FINNEGAN, HENDERSON, FARABOW, GARRETT &
DUNNER LLP
1300 I STREET, NW
WASHINGTON, DC 20005

FORMALITIES LETTER



OC000000007945687*

RECEIVED

MAY 20 2002

TECH CENTER 1600/2900

Date Mailed: 04/24/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE